- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04385433
A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer (PRAVAPREV-01)
-Interventional trials aim at preventing severe RIF occurrence in BC patients selected by individual radiosensitivity:
PRAVAPREV-01 will be the first interventional double blind trial that will offer a personalised strategy to breast cancer patients who will be treated with adjuvant RT after breast conserving surgery:
- By assessing individual risk of severe RIF development
- By offering a statin targeted therapy to the high-risk patients identified.
Study Overview
Status
Conditions
Detailed Description
According to VICAN5 report, near 50% of survivorship breast cancer (BC) patients suffered impairment of their QoL 2 and 5 years after BC diagnosis compared to overall population. In France, adjuvant radiotherapy (RT) is performed to 88.5% of BC patients. Severe toxicities after adjuvant RT such as radio-induced fibrosis (RIF) in BC patients can have a negative impact on quality of life and a marked effect on subsequent psychological outcomes.
However, current practice standards commonly prescribe RT irrespective of the individual radiosensitivity risk. This study propose to identify BC at high RIF risk and to prevent severe RIF occurrence in this selected BC population by the use of anti-fibrotic agent (pravastatin).
How to identify the risk of individual radiosensitivity? Since 1995 a rapid (72 h) radiosensitivity assay based on flow cytometric assessment of radiation-induced CD8 T-lymphocyte apoptosis (RILA) has been developed. A lot of laboratory observed a significant relationship between RILA and toxicities occurrence, in particular in a prospective multicenter French study (NCT00893035, Azria et al, EBioMedicine 2015). Data from this study have validated the use of the NovaGray RILA Breast® test in clinical routine and enabled its CE-mark obtention in 2016.
How to prevent severe RIF occurrence? Few phase II clinical trials have assessed anti-fibrotic properties of some drugs in a preventive setting (pentoxyfilline/vitamine E, ambroxol, ACE inhibitors, amifostine) and showed controversial results regarding efficacy and/ or tolerance. To date, no large phase III clinical trial confirmed these therapeutic strategies in the prevention of severe breast RIF occurrence.
Since 2000, Rho/ROCK pathway inhibition habe been showed, in particular by Pravastatin, was able to prevent and cure severe RIF in different preclinical RIF models. Based on those results, a phase II clinical trial PRAVACUR (NCT01268202) has been conducted,assessing efficacy of 12-months daily pravastatin delivered in patients with established RIF after head and neck radiotherapy. The use of Pravastatin significantly reduced RIF grade in 51% of patients (clinical assessment at 12-months) without any rebound effect after pravastatin completion (Bourgier IJROBP 2019).
This hypothesis is therefore that pravastatin given in a preventive approach will significantly decrease severe breast fibrosis occurrence in a highly selected breast cancer population treated by adjuvant breast RT and considered at high risk of RIF (tailored by the NovaGray RILA Breast® test).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: BOURGIER MD CELINE
- Phone Number: 0467613102
- Email: celine.bourgier@icm.unicancer.fr
Study Locations
-
-
-
Lyon, France, 69000
- Centre Hospitalier Universitaire Lyon Sud
-
-
Alpes-Maritimes
-
Mougins, Alpes-Maritimes, France, 06250
- Centre Azuréen de Cancérologie
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, France, 67000
- Clinique Sainte-Anne
-
-
Corrèze
-
Brive, Corrèze, France, 19100
- Centre Hospitalier de Brive
-
-
Côte d'Or
-
Dijon, Côte d'Or, France, 21079
- Centre Georges-François Leclerc
-
-
Herault
-
Montpellier, Herault, France, 34298
- ICM Val D'Aurelle
-
-
-
-
-
Monaco, Monaco, 98000
- Centre Hospitalier Princesse Grace
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women ≥ 18 years old (no age limit)
- Conservative breast cancer surgery
- High risk level of breast fibrosis identified by the centralized NovaGray RILA Breast® test
- Invasive carcinoma : pT1-T2; pN0 (negative sentinel nodes or axillary nodes dissection) and/or Ductal in situ carcinoma
- Negative surgical margins
- Indication of whole breast irradiation only (with or without boost to tumor bed according to physician discretion)
- Only 3D-conformal RT will be allowed
- Blood sample allowing pravastatin use : serum creatinine ≤ 130 µmol/l; ASAT and ALAT≤ 2N; total bilirubin ≤ 1.5N; CK MM levels < 3 x ULN for women ≥ 70 years (at least 15 days before randomization).
- Negative pregnancy test in women of childbearing potential (β-HCG dosage ≤ 7 days prior to randomization), an adequate contraception should be used from the beginning of the study to 4 weeks after last treatment dose. The women not of reproductive potential are female patients who are postmenopausal (with a minimum of one year without menstruation and without alternative medical cause) or permanently sterilized: e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).
- Must be geographically accessible for follow-up
- Written and dated informed consent
- Affiliated to the French national social security system
Exclusion Criteria:
- Current treatment by : statin, fibrate, ciclosporin, systemic fusidic acid, long-term treatment by corticoids
- History of muscular dystrophy diseases or chronic and/or hereditary muscular diseases
- Patients with distant metastases
- Indications of node irradiation (axillar or supraclavicular or mammary chain)
- T3-4 or N1-3 breast cancer
- Patients who underwent radical mastectomy
- Neoadjuvant systemic therapy (chemotherapy, hormonotherapy, targeted therapies)
- Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years
- Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, infection etc.) which would disrupt extended follow-up
- Untreated hypothyroidism
- Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody
- Pregnant or breastfeeding women
- women of childbearing potential who are unwilling to employ adequate contraception, from the beginning of the study to 4 weeks after last treatment dose
- Known hypersensitivity to pravastatine, or any constituent of the product.
- Patient with alcohol misuse.
- Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EXPERIMENTAL GROUP
RADIOTHERAPY + PRAVASTATIN
|
Patients in the experimental arm will receive:
Other Names:
Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
|
Placebo Comparator: CONTROL GROUP
RADIOTHERAPY + PLACEBO
|
Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
Patients in the standard arm will receive:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of Pravastatin on the occurrence of grade ≥2 breast fibrosis in a selected breast cancer patient population considered at high risk of severe breast fibrosis occurrence
Time Frame: From randomization to 24 months
|
2-year breast fibrosis-free survival (BF-FS) rate
|
From randomization to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of this personalized radiotherapy on Acute toxicities
Time Frame: from randomization to 3 months
|
Incidence of acute effects assessed and graded according to the NCI-CTCAE v5.0 scale; the most severe grade observed during the period per patient will be reported.
|
from randomization to 3 months
|
Impact of this personalized radiotherapy on late toxicities
Time Frame: from randomization to 3 years
|
late side effects assessed and graded according to the NCI-CTCAE v5.0 scale; the most severe grade observed during the period per patient will be reported.
|
from randomization to 3 years
|
Adverse events due to Pravastatine
Time Frame: from randomization to 2 years
|
rate of myalgia and arthralgia
|
from randomization to 2 years
|
Local recurrence
Time Frame: at 1, 2, 3, 5 and 10 years
|
Local recurrence rate
|
at 1, 2, 3, 5 and 10 years
|
Relapse free survival (RFS)
Time Frame: at 1, 2, 3, 5 and 10 years
|
Relapse-free survival (RFS) rates with RFS defined as the time from the date of randomization to the date of the first relapse (including local relapse, or distant metastasis or death (all causes), whichever occurs first.
|
at 1, 2, 3, 5 and 10 years
|
Breast fibrosis-free survival (BF-FS)
Time Frame: at 6 months, at 1 and 3 years
|
BF-FS rates
|
at 6 months, at 1 and 3 years
|
Breast fibrosis-relapse-free survival (BF-RFS)
Time Frame: at 1, 2, 3 and 5 years
|
BF-RFS rates with BF-RFS defined as the time from the date of randomization to the date of the first relapse (including local relapse, or distant metastasis or death (all causes) or the first documented grade ≥2 breast fibrosis whichever occurs first.
|
at 1, 2, 3 and 5 years
|
Specific quality of life measure for breast cancer patient
Time Frame: at baseline, 5 weeks after RT and 6, 12, 18, 24 and 36 months , at 4 and 5 years
|
EORTC QLQ-C30 questionnaires : minimum value = 1 (no effect) maximum value = 4 (bad effect)
|
at baseline, 5 weeks after RT and 6, 12, 18, 24 and 36 months , at 4 and 5 years
|
Specific quality of life measure for breast cancer patient
Time Frame: at baseline, 5 weeks after RT and 6, 12, 18, 24 and 36 months , at 4 and 5 years
|
QLQ-BR23 questionnaires:minimum value = 1 (no effect) maximum value = 4 (bad effect)
|
at baseline, 5 weeks after RT and 6, 12, 18, 24 and 36 months , at 4 and 5 years
|
the Cosmetic affect
Time Frame: at baseline, at 12 months and at 2 years of pravastatin/Placebo treatment
|
rate of the acute and rate of later side effects with photographics
|
at baseline, at 12 months and at 2 years of pravastatin/Placebo treatment
|
feasibility of a new production technique for NovaGray RILA Breast® test
Time Frame: at baseline
|
test score sensitivity
|
at baseline
|
Stability of the test
Time Frame: at 12 months
|
The radiation-induced lymphocyte apoptosis (RILA) assay is the leading candidate as a biological predictor of radiotherapy toxicity
|
at 12 months
|
Collaborators and Investigators
Investigators
- Study Chair: Céline Bourgier, MD, ICM Co. Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROICM 2019-11 PRA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on EXPERIMENTAL ARM
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHPV | Related Malignancy | Related CarcinomaUnited States
-
Tata Memorial HospitalRecruiting
-
Le Mans UniversiteActive, not recruiting
-
Centre hospitalier de l'Université de Montréal...RecruitingHead and Neck Cancer | Oligoprogressive | Metastatic CancerCanada
-
University Hospital, BrestRecruiting
-
Qure Healthcare, LLCProgenity, Inc.CompletedPre-EclampsiaUnited States
-
Institut Claudius RegaudRecruiting
-
Qure Healthcare, LLCEthos LaboratoriesCompletedPain | Pain, ChronicUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)Completed
-
UNICANCERNational Cancer Institute, FranceActive, not recruiting